Hydrophobic cavity formed by oligopeptide for doxorubicin delivery based on dendritic poly(L-lysine).

scientific article

Hydrophobic cavity formed by oligopeptide for doxorubicin delivery based on dendritic poly(L-lysine). is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1080/09205063.2014.938979
P698PubMed publication ID25040893

P50authorTakuro NiidomeQ42807839
P2093author name stringKazuto Watanabe
Takeshi Mori
Yoshiki Katayama
Kayo Takahashi
Kenshiro Naoyama
Hisayo Yamauchi
P2860cites workPeptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumorsQ39653208
Preparation and cytotoxic activity of poly(ethylene glycol)-modified poly(amidoamine) dendrimers bearing adriamycinQ40025224
Biodistribution characteristics of amino acid dendrimers and their PEGylated derivatives after intravenous administrationQ40310715
Antitumor efficacy of a novel polymer-peptide-drug conjugate in human tumor xenograft models.Q40368363
Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy.Q40453716
Liposomal doxorubicin (Caelyx) in symptomatic androgen-independent prostate cancer (AIPC)--delayed response and flare phenomenon should be consideredQ40641342
Biodistribution studies of nanoparticles using fluorescence imaging: a qualitative or quantitative method?Q43238303
A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems.Q43963775
In vitro gene transfection using dendritic poly(L-lysine).Q43992769
Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicityQ29614981
Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation styleQ33514578
Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth.Q33732629
Dendrimers in drug researchQ34291645
Designing dendrimers for biological applicationsQ34473653
Cationic poly-L-lysine dendrimer complexes doxorubicin and delays tumor growth in vitro and in vivoQ34635753
A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomasQ35130646
Dendrimers and dendritic polymers in drug deliveryQ36022312
Dendrimer-drug interactions.Q36323316
Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer.Q36671058
Nanocarriers enhance Doxorubicin uptake in drug-resistant ovarian cancer cells.Q36853778
Nanoparticles for tumor targeted therapies and their pharmacokineticsQ37722776
Targeting nanoparticles to cancer.Q37728139
Doxorubicin-conjugated dendrimer/collagen hybrid gels for metastasis-associated drug delivery systemsQ39242370
Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor modelsQ39414448
Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker.Q39593858
P433issue13
P921main subjectdoxorubicinQ18936
hydrophobicityQ41854968
P304page(s)1362-1373
P577publication date2014-07-21
P1433published inJournal of Biomaterials Science. Polymer EditionQ15760949
P1476titleHydrophobic cavity formed by oligopeptide for doxorubicin delivery based on dendritic poly(L-lysine)
P478volume25

Reverse relations

cites work (P2860)
Q38755622Dendrimer-mediated approaches for the treatment of brain tumor.
Q41734074Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy.
Q38779839Peptide-Decorated Dendrimers and Their Bioapplications
Q28085438Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery

Search more.